Present and future of FDG-PET/CT in ovarian cancer

被引：31

作者：

Kitajima, Kazuhiro ^{[1
]}

Murakami, Koji ^{[2
]}

Sakamoto, Setsu ^{[3
]}

Kaji, Yasushi ^{[4
]}

Sugimura, Kazuro ^{[5
]}

机构：

[1] Inst Biomed Res & Innovat, Dept PET Diag, Chuo Ku, Kobe, Hyogo 6500047, Japan

[2] Keio Univ, Sch Med, Div Nucl Med, Dept Diagnost Radiol, Tokyo, Japan

[3] Dokkyo Med Univ Hosp, PET Ctr, Mibu, Tochigi, Japan

[4] Dokkyo Univ, Sch Med, Dept Radiol, Mibu, Tochigi 32102, Japan

[5] Kobe Univ, Dept Radiol, Grad Sch Med, Kobe, Hyogo 657, Japan

来源：

ANNALS OF NUCLEAR MEDICINE | 2011年 / 25卷 / 03期

关键词：

FDG; PET/CT; Ovarian cancer; Staging; Restaging; POSITRON-EMISSION-TOMOGRAPHY; PET/CONTRAST-ENHANCED CT; RECURRENT OVARIAN; COMPUTED-TOMOGRAPHY; F-18-FDG PET/CT; NEOADJUVANT CHEMOTHERAPY; DIAGNOSTIC-ACCURACY; INTEGRATED PET/CT; THERAPY RESPONSE; NEXT-GENERATION;

D O I：

10.1007/s12149-010-0449-8

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Integrated FDG-PET/CT has been used successfully for the diagnosis, staging, restaging, therapy monitoring and prognostic prediction of ovarian cancer as well as various other malignant tumors. Compared with conventional PET/non-contrast CT images, combined PET/contrast-enhanced CT images with intravenous iodine contrast medium and sufficient radiation dose may contribute to a more accurate diagnosis with higher confidence. In the future, tracers other than FDG and integrated PET/MRI will be realized. We herein review the place and role of FDG-PET/CT in the management of ovarian cancer, discussing its usefulness and limitations in the imaging of these patients.

引用

页码：155 / 164

页数：10

共 59 条

[1] MRI of sonographically indeterminate adnexal masses [J].

Adusumilli, Saroja ;

Hussain, Hero K. ;

Caoili, Elaine M. ;

Weadock, William J. ;

Murray, John P. ;

Johnson, Timothy D. ;

Chen, Qixuan ;

Desjardins, Benoit .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 187 (03) :732-740

[2] Combined PET/MRI: a new dimension in whole-body oncology imaging? [J].

Antoch, Gerald ;

Bockisch, Andreas .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 :113-120

[3] Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer [J].

Avril, N ;

Sassen, S ;

Schmalfeldt, B ;

Naehrig, J ;

Rutke, S ;

Weber, WA ;

Werner, M ;

Graeff, H ;

Schwaiger, M ;

Kuhn, W .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7445-7453

[4] Contribution of whole-body 18FDG PET imaging in the management of cervical cancer [J].

Belhocine, T ;

Thille, A ;

Fridman, V ;

Albert, A ;

Seidel, L ;

Nickers, P ;

Kridelka, F ;

Rigo, P .

GYNECOLOGIC ONCOLOGY, 2002, 87 (01) :90-97

[5]

Beyer T, 2000, J NUCL MED, V41, P1369

[6]

BOOTH SJ, 2008, BJOG, V15, P894

[7] Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes [J].

Bristow, RE ;

Giuntoli, RL ;

Pannu, HK ;

Schulick, RD ;

Fishman, EK ;

Wahl, RL .

GYNECOLOGIC ONCOLOGY, 2005, 99 (02) :294-300

[8]

Bristow RE, 2000, CANCER, V89, P1532, DOI 10.1002/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO

[9]

2-A

[10] Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT [J].

Bristow, RE ;

del Carmen, MG ;

Pannu, HK ;

Cohade, C ;

Zahurak, ML ;

Fishman, EK ;

Wahl, RL ;

Montz, FJ .

GYNECOLOGIC ONCOLOGY, 2003, 90 (03) :519-528

← 1 2 3 4 5 6 →